Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125356482 | 12535648 | 2 | F | 20160802 | 20160817 | 20160707 | 20160829 | PER | US-ASTRAZENECA-2016SE70677 | ASTRAZENECA | 25516.00 | DY | F | Y | 89.80000 | KG | 20160829 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125356482 | 12535648 | 1 | PS | BRILINTA | TICAGRELOR | 1 | Oral | Y | N | 22433 | TABLET | ||||||||
| 125356482 | 12535648 | 2 | SS | BRILINTA | TICAGRELOR | 1 | Oral | Y | N | 22433 | TABLET | ||||||||
| 125356482 | 12535648 | 3 | SS | BRILINTA | TICAGRELOR | 1 | Oral | Y | N | 22433 | 90 | MG | TABLET | Q12H | |||||
| 125356482 | 12535648 | 4 | SS | BRILINTA | TICAGRELOR | 1 | Oral | Y | N | 22433 | 90 | MG | TABLET | Q12H | |||||
| 125356482 | 12535648 | 5 | SS | ATENOLOL. | ATENOLOL | 1 | Oral | U | 0 | 1 | DF | TABLET | QD | ||||||
| 125356482 | 12535648 | 6 | C | ASPIRIN. | ASPIRIN | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 7 | C | BENICAR | OLMESARTAN MEDOXOMIL | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 8 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 9 | C | GLIPIZIDE. | GLIPIZIDE | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 10 | C | HYDRALAZINE | HYDRALAZINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 11 | C | ISOSORBIDE MONONITRATE. | ISOSORBIDE MONONITRATE | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 12 | C | LANTUS SOLOSTAR | INSULIN GLARGINE | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 13 | C | LOVASTATIN. | LOVASTATIN | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 14 | C | NITROSTAT | NITROGLYCERIN | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 15 | C | NOVOLOG | INSULIN ASPART | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 16 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | 0 | ||||||||||||
| 125356482 | 12535648 | 17 | C | PLAVIX | CLOPIDOGREL BISULFATE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125356482 | 12535648 | 1 | Acute coronary syndrome |
| 125356482 | 12535648 | 2 | Coronary artery disease |
| 125356482 | 12535648 | 3 | Acute coronary syndrome |
| 125356482 | 12535648 | 4 | Coronary artery disease |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125356482 | 12535648 | Agitation | |
| 125356482 | 12535648 | Dyspnoea |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125356482 | 12535648 | 1 | 2015 | 20150802 | 0 | |
| 125356482 | 12535648 | 2 | 2015 | 20150802 | 0 | |
| 125356482 | 12535648 | 3 | 20160713 | 20160802 | 0 | |
| 125356482 | 12535648 | 4 | 20160713 | 20160802 | 0 | |
| 125356482 | 12535648 | 5 | 20160622 | 0 |